Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | DRD3 | P35462 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | HRH1 | P35367 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494421 | 0.95 | DRD2 (0.54) | HTR7HRH3DRD2DRD3HTR1A | |
| SCHEMBL2495273 | 0.94 | HTR1A (0.51) | HTR7HRH3DRD2DRD3HTR1A | |
| SCHEMBL2493715 | 0.90 | HTR7 (0.50) | HTR7HRH3DRD2DRD3HTR1A | |
| SCHEMBL2496615 | 0.90 | HTR7 (0.43) | HTR7HRH3DRD2DRD3HTR1A | |
| SCHEMBL2500052 | 0.89 | HTR1A (0.48) | HTR7HRH3DRD2DRD3HTR1A | |
| SCHEMBL2494194 | 0.88 | DRD2 (0.54) | HTR7HRH3DRD2DRD3HTR1A | |
| SCHEMBL2469807 | 0.87 | HTR7 (0.64) | HTR7DRD2DRD3TSHRALDH1A1 | |
| SCHEMBL2494400 | 0.87 | TP53 (0.53) | HTR7HRH3DRD2DRD3HTR1A | |
| SCHEMBL2500360 | 0.87 | HTR7 (0.49) | HTR7HRH3DRD2DRD3HTR1A | |
| SCHEMBL2496540 | 0.86 | HTR7 (0.43) | HTR7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | claimed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-2373629-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-12 | — | — | EP | claimed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | claimed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2373629-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BCL2, BAX, BCL2A1 | HTR7 2753/4885HRH3 2644/4885DRD2 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.